The application of ranibizumab in therapy of diabetic macular edema – own observations

Article Sidebar

PDF (Język Polski)


Published: Sep 30, 2014
Keywords:
diabets, diabetic macular edema, vision loss, ranibizumab

Main Article Content

Małgorzata Marczak
Oddział Okulistyczny Wojewódzkiego Szpitala Podkarpackiego, Krosno

Abstract

Diabetes is a serious health problem which affects c. 226 million people all over the world. Diabetic macular edema (DME) is the main cause of vision loss and may develop at any stage of progressing retinopathy. The complex nature of pathophysiology of DME is connected, among other factors, with retinal hypoxia and the increased activity of the VEGF factor. The laser photocoagulation has been the routine treatment of the retina for many years however in numerous cases it is insufficient. In 2011 the use of ranibizumab was registered in Poland. The effectiveness and safety of the application of ranibizumab have been proved in numerous clinical tests both in monotherapy and combined with other methods of treatment. Untreated chronic diabetes macular edema results in irreversible deterioration of vision.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Marczak M. The application of ranibizumab in therapy of diabetic macular edema – own observations. Ophthatherapy [Internet]. 2014Sep.30 [cited 2024Nov.22];1(3):165-9. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/685
Issue
Vol 1 No 3 (2014)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Chmielewska K, Robaszkiewicz J, Kosatka M. Rola nabłonka barwnikowego siatkówki w patogenezie cukrzycowego obrzęku plamki i jego leczeniu. Klinika Okulistyczna. 2008: 7-9.
2. Gupta N, Mabsoor S, Sharma A et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013; 7: 4-10.
3. Nguyen QD, Tatlipinar S, Shah SM et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006; 142: 961-9.
4. Kubicka-Trząska A. Doszklistkowe iniekcje ranibizumabu w leczeniu cukrzycowego obrzęku plamki. Klinika Okulistyczna. 2010: 10-2.
5. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987; 94(7): 761-74.
6. Nguyen QD, Shah SM, Heier JS et al. Primary end point (six months) results of the Ranibizumab for Edema of the macula in Diabetes (READ-2) study. Ophthalmology. 2009; 116: 2175-81.
7. Chun DW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with centerinvolving clinically significant diabetic macular edema. Opththalmology. 2006; 113(10): 1706-12.
8. Mitchell P, Bandello F,. Schmidt-Erfurth U et al; RESTORE study group. The RESTORE study : ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011; 118(4): 615-25.
9. Novartis – monografia produktu leczniczego Lucentis.
10. Charakterystyka produktu leczniczego – Aneks 09/2014